here is one that i like alot, CTIC. a drug company that is in the process of producing a line of drugs for the treatment of cancer. they have been strapped for operating cash this year and it has hurt the stock. recently severed a long stranding relationship with another drug company SPPI who got to walk away with the drug they were both working on leaving CTIC in a weakened position. they were able to bring in investors to raise operating capital and most recently a single hedge fund put up 30 million to buy convertible warrants that could be converted into stock at 1.70 per share which they immediately did. they also own the rights approx. 5 million more shares at 1.70. i have recently been acquiring shares and now own close to 20000 shares ranging from 1.68, which was my initial entry point to 1.52 which has been a recent low. im putting up a chart along with something that The Motley Fool has had to say about the stock. i am not an advocate of Motley Fool but noticed this and thought it was revelant.
It's been a rocky year for cancer-drug developer Cell Therapeutics, which had to turn over the rights to Zevalin to Spectrum Pharmaceutical (Nasdaq: SPPI) as it rushed to raise cash. And then an arbitrator forced Cell Therapeutics to pay $4 million in expenses to its one-time collaborator. Now it watches Spectrum heat up while it seeks out first-line FDA approval for Zevalin in non-Hodgkin's lymphoma cases.
Yet Cell Therapeutics' own therapy for the illness, pixantrone, is also under FDA consideration. At least one analyst thinks there may be some problems with the drug, but Cell Therapeutics was able to cause the markets to tremble in June with a clinical trial purporting to show that pixantrone was successful at treating aggressive non-Hodgkin's lymphoma. If the FDA approves the drug, as CAPS member xnautis believes will happen, Cell Therapeutics' stock should get a nice injection of adrenaline: "CTIC has just asked the FDA to approve pixantrone for refractory aggressive non-Hodgkin's lymphoma, a form of cancer. It's still very
here is the weekly chart. remember only if you can afford to lose the money but this is a decent chart and you could put your money into worse setups and right now it is a triple off of recent lows.
It's been a rocky year for cancer-drug developer Cell Therapeutics, which had to turn over the rights to Zevalin to Spectrum Pharmaceutical (Nasdaq: SPPI) as it rushed to raise cash. And then an arbitrator forced Cell Therapeutics to pay $4 million in expenses to its one-time collaborator. Now it watches Spectrum heat up while it seeks out first-line FDA approval for Zevalin in non-Hodgkin's lymphoma cases.
Yet Cell Therapeutics' own therapy for the illness, pixantrone, is also under FDA consideration. At least one analyst thinks there may be some problems with the drug, but Cell Therapeutics was able to cause the markets to tremble in June with a clinical trial purporting to show that pixantrone was successful at treating aggressive non-Hodgkin's lymphoma. If the FDA approves the drug, as CAPS member xnautis believes will happen, Cell Therapeutics' stock should get a nice injection of adrenaline: "CTIC has just asked the FDA to approve pixantrone for refractory aggressive non-Hodgkin's lymphoma, a form of cancer. It's still very
here is the weekly chart. remember only if you can afford to lose the money but this is a decent chart and you could put your money into worse setups and right now it is a triple off of recent lows.

Comment